CCEL: financial statements from SEC — TradeAlmanac

CCEL

Cryo-Cell International, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Feb 28, 2026	Aug 31, 2025	May 31, 2025	Feb 28, 2025	Aug 31, 2024	May 31, 2024
Revenue	8m	8m	8m	8m	8m	8m
Cost of revenue	2m	2m	2m	2m	2m	2m
Research and development	65,761	61,625	131,711	98,143	193,933	241,085
Selling, general and administrative	5m	4m	4m	5m	4m	4m
Operating expenses	7m	6m	6m	7m	7m	7m
Operating income	765,134	2m	1m	1m	1m	1m
Interest expense	—	—	—	—	—	329,273
Pre-tax income	70,309	1m	575,103	533,718	1m	1m
Income tax	23,201	436,588	219,318	250,863	328,186	816,390
Net income	47,108	749,408	355,785	282,855	1m	655,790
Earnings per share	0.01	0.09	0.04	0.03	0.13	0.08
Earnings per share, diluted	0.01	0.09	0.04	0.03	0.13	0.08
Weighted average shares	8m	8m	8m	8m	8m	8m
Weighted average shares, diluted	8m	8m	8m	8m	8m	8m

Balance sheet

Metric	Feb 28, 2026	Nov 30, 2025	Aug 31, 2025	May 31, 2025	Feb 28, 2025	Nov 30, 2024	Aug 31, 2024	May 31, 2024
Cash and equivalents	249,672	319,031	265,207	137,491	223,122	560,960	197,437	469,195
Short-term investments	3m	3m

Cash flow

Metric	Feb 28, 2026	Aug 31, 2025	May 31, 2025	Feb 28, 2025	Aug 31, 2024	May 31, 2024
Operating cash flow	651,827	—	—	954,063	—	—
Depreciation and amortisation	244,212	185,693	190,102	248,010

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)